ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,888.33
0.24%
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs Yen
157.2625
0.00%
Brent Oil
80.875
-0.52%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Kos Pharmaceuticals (KOSP)

  7. Kos Pharmaceuticals (KOSP) ニュース

KOSP

Kos (KOSP)

Kos Pharmaceuticals
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:KOSP
日付受信時刻ニュースソース見出しコード企業名
2006/12/1323 : 22PR Newswire (US)Abbott Acquires a Majority of Shares of Kos Pharmaceuticals, Inc.NASDAQ:KOSPKos Pharmaceuticals
2006/12/0505 : 36PR Newswire (US)Abbott's Acquisition of Kos Pharmaceuticals, Inc. Clears Antitrust ReviewNASDAQ:KOSPKos Pharmaceuticals
2006/11/1503 : 45PR Newswire (US)Abbott Laboratories Commences Tender Offer for All Outstanding Shares of Kos Pharmaceuticals, Inc.NASDAQ:KOSPKos Pharmaceuticals
2006/11/0921 : 00Business WireKos Reports a 17% Increase in Revenue, Earnings Per Share of $0.71, and Solid Cash Flow from OperationsNASDAQ:KOSPKos Pharmaceuticals
2006/11/0801 : 21PR Newswire (US)Holland & Knight Leads Kos Pharmaceuticals, Inc. Buyout by Abbott Laboratories for $3.7 BillionNASDAQ:KOSPKos Pharmaceuticals
2006/11/0621 : 50PR Newswire (US)Abbott to Expand Presence in Lipid Management Market With Acquisition of Kos PharmaceuticalsNASDAQ:KOSPKos Pharmaceuticals
2006/11/0323 : 31Business WireKos to Report Third Quarter Results on November 9, 2006 Conference Call at 8:30 A.M. ETNASDAQ:KOSPKos Pharmaceuticals
2006/09/2205 : 41Business WireKos Announces Positive Overall Results for Two Phase III Trials of Icatibant for the Treatment of Hereditary AngioedemaNASDAQ:KOSPKos Pharmaceuticals
2006/09/1920 : 00Business WireKos to Present at the UBS Global Life Sciences ConferenceNASDAQ:KOSPKos Pharmaceuticals
2006/09/1823 : 05Business WireKos Pharmaceuticals Announces Compliance with NASDAQ Continued Listing RequirementsNASDAQ:KOSPKos Pharmaceuticals
2006/09/0621 : 30PR Newswire (US)SkyePharma and Mundipharma Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in EuropeNASDAQ:KOSPKos Pharmaceuticals
2006/08/1705 : 15Business WireKos Announces Notice from Nasdaq Regarding Potential DelistingNASDAQ:KOSPKos Pharmaceuticals
2006/08/1001 : 42PR Newswire (US)Arisaph Pharmaceuticals Announces Second Closing of $8 Million Equity InvestmentNASDAQ:KOSPKos Pharmaceuticals
2006/08/0820 : 00Business WireKos Reports 25% Increase in Revenue, Solid Financial Results and Progress in Research and DevelopmentNASDAQ:KOSPKos Pharmaceuticals
2006/07/2723 : 26Business WireKos to Report Second Quarter Results on August 8, 2006 Conference Call at 8:30 a.m. ETNASDAQ:KOSPKos Pharmaceuticals
2006/07/2523 : 39Business WireKos Reports Summary Results from Clinical Study on Benefits of Combining Aspirin with Optimized Niaspan(R) CFNASDAQ:KOSPKos Pharmaceuticals
2006/07/1223 : 18Business WireKos Submits Supplemental New Drug Application To FDA For New Niaspan(R) CF Range of ProductsNASDAQ:KOSPKos Pharmaceuticals
2006/06/2015 : 00Business WireNiaspan(R) Combined with Low/Moderate Dosed Statin Achieves Better Total Lipid Control vs. Higher Dose Statin Monotherapy or ZoNASDAQ:KOSPKos Pharmaceuticals
2006/06/0722 : 42Business WireKos Announces Completion of Patient Randomization for Jerini's Phase III Clinical Trials of Icatibant for the Subcutaneous TreaNASDAQ:KOSPKos Pharmaceuticals
2006/05/0920 : 00Business WireKos Reports Continued Double Digit Increase in Revenue, Financial Results in Line with Guidance and Authorization for up to 7 MNASDAQ:KOSPKos Pharmaceuticals
2006/05/0821 : 00PR Newswire (US)SkyePharma and Kos to Host Teleconference Today on US Marketing and Distribution Agreement for Flutiform(TM)NASDAQ:KOSP
2006/05/0816 : 00PR Newswire (US)SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in the United StatesNASDAQ:KOSPKos Pharmaceuticals
2006/05/0523 : 51Business WireCORRECTING and REPLACING Kos Announces Presentation at the Bank of America 2006 Healthcare ConferenceNASDAQ:KOSPKos Pharmaceuticals
2006/05/0521 : 30Business WireKos Announces Presentation at the Bank of America 2006 Healthcare ConferenceNASDAQ:KOSPKos Pharmaceuticals
2006/04/2602 : 09Business WireKos Announces Presentation at the Deutsche Bank 2006 Healthcare ConferenceNASDAQ:KOSPKos Pharmaceuticals
2006/04/2506 : 06Business WireKos Pharmaceuticals to Report First Quarter Results on May 9, 2006 Conference Call at 8:30 A.M. ETNASDAQ:KOSPKos Pharmaceuticals
2006/04/1923 : 25Business WireKos Announces Annual Shareholders Meeting April 27, 2006NASDAQ:KOSPKos Pharmaceuticals
2006/04/1303 : 51Business WireCenters for Medicare and Medicaid Services (CMS) Advises Plans Niaspan(R) is Now a Part D Eligible Drug; Confirms Niaspan as anNASDAQ:KOSPKos Pharmaceuticals
2006/03/0122 : 36Business WireKos Announces Presentation at the Lehman Brothers Ninth Annual Global Healthcare ConferenceNASDAQ:KOSPKos Pharmaceuticals
2006/02/2822 : 52Business WireKos Announces Presentation at the SG Cowen 26th Annual Health Care ConferenceNASDAQ:KOSPKos Pharmaceuticals
 Showing the most relevant articles for your search:NASDAQ:KOSP

最近閲覧した銘柄

USOTC
RHHBY
Roche (QX)
CCOM
SILVER
SILVER
NYSE
NKE
Nike
COIN
SOLUSD
Solana
AMEX
XLF
Financial Select Sector
USI
USTECH100
US Tech 100
NYSE
KO
Coca Cola
NYSE
DIS
Walt Disney
FX
USDGBP
US Dollar vs Sterling
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
ADDYY
Adidas (QX)
NYSE
MCD
McDonalds
PM
XAUUSD
Gold vs US Dollar
NYSE
MRK
Merck
AMEX
SPY
SPDR S&P 500
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有